[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338031-105":59,"doc-detail-338031-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-safety-and-patient-reported-outcome-of-immune-checkpoint-inhibitor-in-gynecologic-cancers-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials","Efficacy, safety, and patient-reported outcome of immune checkpoint inhibitor in gynecologic cancers - A systematic review and meta-analysis of randomized controlled trials","","Immune checkpoint inhibitors (ICIs) have improved survival across multiple malignancies, prompting evaluation in gynecologic cancers. A systematic review and meta-analysis retrieved evidence from major electronic databases and included 12 randomized controlled trials with 8,034 patients. Compared with control, the ICI group showed longer overall survival and better progression-free survival, with no clear difference in overall treatment-related adverse events. Immune-related adverse events were more frequent, while overall QOL score changes were not significantly different; however, definitive QOL deterioration occurred later with ICI therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-safety-and-patient-reported-outcome-of-immune-checkpoint-inhibitor-in-gynecologic-cancers-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/338031/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-safety-and-patient-reported-outcome-of-immune-checkpoint-inhibitor-in-gynecologic-cancers-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/338031.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of this study?","Question",{"text":112,"@type":113},"To evaluate the efficacy, safety, and patient-reported outcomes of immune checkpoint inhibitor therapy in gynecologic cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did immune checkpoint inhibitors affect survival and progression?",{"text":117,"@type":113},"Compared with control, the ICI group demonstrated longer overall survival and improved progression-free survival.",{"name":119,"@type":110,"acceptedAnswer":120},"What safety and quality-of-life findings were reported?",{"text":121,"@type":113},"Overall treatment-related adverse events were not significantly different, but immune-related adverse events were more common. Mean QOL changes were not significantly different, while time to definitive QOL deterioration was longer with ICI.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338031,1790622838,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","PLOS ONE  \nOPEN ACCESS  \nCitation: Kusuma F, Glenardi G, Mangkuliguna G, Winarto H, Purwoto G, Utami TW, et al. (2024) Efficacy, safety, and patient-reported outcome of immune checkpoint inhibitor in gynecologic cancers: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE 19(8): e0307800 . [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0307800  \nEditor: Mirosława Pu¨sku¨llu¨oğlu, Maria Sklodowska-Curie National Research Institute of Oncology Krakow, POLAND  \nReceived: May 15, 2024  \nAccepted: July 11, 2024  \nPublished: August 12, 2024  \nCopyright: © 2024 Kusuma et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData Availability Statement: All relevant data are within the manuscript and its Supporting information files.  \nFunding: The author(s) received no specific funding for this work.  \nCompeting interests: The authors have declared that no competing interests exist.  \nRESEARCH ARTICLE  \nEfficacy, safety, and patient-reported outcome of immune checkpoint inhibitor in gynecologic cancers: A systematic review and metaanalysis of randomized controlled trials  \nFitriyadi Kusuma1☯*, Glenardi Glenardi1,2,3☯ *, Ghea Mangkuliguna2☯,  \nHariyono Winarto1‡, Gatot Purwoto1‡, Tofan Widya Utami1‡, Tricia Dewi Anggraeni1‡  \n1 Division of Oncology Gynecology, Department of Obstetrics and Gynecology, Dr. Cipto Mangunkusumo Hospital, Greater Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia, 2 School of Medicine and Health Sciences, Department of Medicine, Atma Jaya Catholic University of Indonesia, North Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia, 3 Lewoleba General Hospital, Lembata Island, East Nusa Tenggara, Indonesia  \n☯ These authors contributed equally to this work.  \n‡ HW, GP, TWU and TDA also contributed equally to this work.  \n* [kusumafitriyadi@gmail.com](kusumafitriyadi@gmail.com) (FK); [glenardihalim@gmail.com](glenardihalim@gmail.com) (GG)  \nAbstract  \nOver the past decades, immune checkpoint inhibitors (ICIs) have shown dramatic efficacy in improving survival rates in multiple malignancies. Recently, gynecological cancer patients also showed to respond favorably to ICI treatment. This study aimed to evaluate the efficacy, safety, and patient-reported outcomes of ICI therapy in gynecological cancers. We conducted a systematic review and meta-analysis by retrieving literature from multiple electronic databases, such as MEDLINE, ScienceDirect, EBSCO, ProQuest, and Google Scholar. The protocol used in this study has been registered in PROSPERO (CRD42022369529) . We included a total of 12 trials involving 8 therapies and 8,034 patients. ICI group demonstrated a longer OS (HR: 0.807; 95% CI: 0.719, 0.907; p = 0.000) and greater PFS improvement (HR: 0.809; 95% CI: 0.673, 0.973; p = 0.024) compared to the control group. There was no significant difference in the incidence of treatment-related adverse events [RR: 0.968; 95%CI: 0.936, 1.001; p = 0.061], but a higher incidence of immune-related adverse events (IRAEs) was observed in the ICI group (RR: 3.093; 95%CI:  \n1.933, 4.798; p = 0.000) . Although the mean changes of QOL score from baseline was not significantly different between both groups (SMD: 0.048; 95% CI: -0. 106, 0.202; p = 0.542), the time to definitive QOL deterioration was longer in the ICI group (HR: 0.508; 95% CI: 0.461, 0.560; p = 0.000) . Despite having a higher incidence of IRAE, ICI was shown to improve survival rates and QOL of patients. Thus, it should be considered as a new standard of care for gynecologic cancers, especially in advanced stages.  \nIntroduction  \nImmune checkpoint inhibitors (ICIs), such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed death-1 (PD-1), and its ligand (PD-L1), represent a breakthrough in cancer treatment that succ","cbCaij1DGu81NGht","https://ap.wps.com/l/cbCaij1DGu81NGht","pdf",542226,22,"English","# Abstract\n# Introduction\n# Materials and methods","[{\"question\":\"What is the main purpose of this study?\",\"answer\":\"To evaluate the efficacy, safety, and patient-reported outcomes of immune checkpoint inhibitor therapy in gynecologic cancers.\"},{\"question\":\"How did immune checkpoint inhibitors affect survival and progression?\",\"answer\":\"Compared with control, the ICI group demonstrated longer overall survival and improved progression-free survival.\"},{\"question\":\"What safety and quality-of-life findings were reported?\",\"answer\":\"Overall treatment-related adverse events were not significantly different, but immune-related adverse events were more common. Mean QOL changes were not significantly different, while time to definitive QOL deterioration was longer with ICI.\"}]","Efficacy, safety, and patient-reported outcome of immune checkpoint inhibitor in gynecologic cancers - A systematic review and meta-analysis of randomized controlled trials | PDF",1790021635,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f526655f6bcae3d75dcb9dbc8c16ec3e.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b1ff9cca86bd41cde98f4389e0c6e03.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41045213719c927414fa38673b4ee1c7.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44a117905147af30415aa3ff2d34f533.webp",980,1268]